Fig. 5 | Signal Transduction and Targeted Therapy

Fig. 5

From: Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases

Fig. 5

Pleiotropic influence of transcriptional co-activators in driving gastrointestinal cancers. The malignancies associated with GI tract contribute to one-third of all cancer-related deaths, with colorectal cancer, liver cancer, stomach cancer, esophageal cancer, and pancreatic cancer being the main contributors. a Transcriptional co-activators DDX27, KMT2A, CBP, BRD4, and YAP interacts with diverse transcription factors to facilitate colorectal cancer progression. b YAP, TAZ, CBP/p300, PPM1G, and HBx are significantly associated with liver cancer progression. c Gastric/Stomach cancer progression is modulated chiefly by YAP/TAZ and TRIM24-mediated regulation of WNT/β-CATENIN pathway, DDX5-mediated upregulation of mTOR/S6K1 pathway, and BRD4/E2F1-mediated upregulation of miR-106b-5p. d Transcriptional co-activators CRTC1 and ZNF282 have been reported to physically interact with transcription factors CREB and E2F1, respectively, fostering esophageal cancer growth and metastasis. e The co-activators PIWIL1, CBP/p300, SETD8, YAP, and BRD4 have been established to be key regulators of pancreatic cancer promotion and proliferation. PDAC pancreatic ductal carcinoma, APC/C anaphase promoting complex/cyclosome. This figure was created using BioRender (https://biorender.com/)

Back to article page